- Home
- YXT vs GUTS Comparison
YXT vs GUTS Comparison
Compare YXT & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YXT
- GUTS
- Stock Information
- Founded
- YXT 2011
- GUTS 2010
- Country
- YXT China
- GUTS United States
- Employees
- YXT N/A
- GUTS N/A
- Industry
- YXT
- GUTS
- Sector
- YXT
- GUTS
- Exchange
- YXT NYSE
- GUTS NYSE
- Market Cap
- YXT 129.2M
- GUTS 110.1M
- IPO Year
- YXT 2024
- GUTS 2024
- Fundamental
- Price
- YXT $2.03
- GUTS $1.82
- Analyst Decision
- YXT
- GUTS Buy
- Analyst Count
- YXT 0
- GUTS 2
- Target Price
- YXT N/A
- GUTS $18.00
- AVG Volume (30 Days)
- YXT 94.4K
- GUTS 373.0K
- Earning Date
- YXT 02-21-2025
- GUTS 02-02-2025
- Dividend Yield
- YXT N/A
- GUTS N/A
- EPS Growth
- YXT N/A
- GUTS N/A
- EPS
- YXT 3.06
- GUTS N/A
- Revenue
- YXT $48,030,651.00
- GUTS $97,000.00
- Revenue This Year
- YXT N/A
- GUTS N/A
- Revenue Next Year
- YXT N/A
- GUTS N/A
- P/E Ratio
- YXT $0.65
- GUTS N/A
- Revenue Growth
- YXT N/A
- GUTS N/A
- 52 Week Low
- YXT $1.82
- GUTS $1.74
- 52 Week High
- YXT $11.00
- GUTS $14.50
- Technical
- Relative Strength Index (RSI)
- YXT N/A
- GUTS 41.31
- Support Level
- YXT N/A
- GUTS $1.77
- Resistance Level
- YXT N/A
- GUTS $2.10
- Average True Range (ATR)
- YXT 0.00
- GUTS 0.16
- MACD
- YXT 0.00
- GUTS -0.01
- Stochastic Oscillator
- YXT 0.00
- GUTS 9.18
About YXT YXT.COM GROUP HOLDING LIMITED SPON ADS EA REP 3 CL A SHS
Yxt.Com Group Holding Ltd operates as a technology company. The company has created a SaaS model that integrates software and content, assisting customers in the digital transformation of corporate learning. The company operates in the People's Republic of China.
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.